Pfizer Inc. (NYSE:PFE) Shares Bought by D.A. Davidson & CO.

D.A. Davidson & CO. raised its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 10.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,938,501 shares of the biopharmaceutical company's stock after buying an additional 179,060 shares during the period. D.A. Davidson & CO.'s holdings in Pfizer were worth $49,122,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in PFE. Brighton Jones LLC boosted its position in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its position in shares of Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares during the period. Victory Capital Management Inc. lifted its position in shares of Pfizer by 47.8% in the 4th quarter. Victory Capital Management Inc. now owns 5,152,861 shares of the biopharmaceutical company's stock worth $136,705,000 after purchasing an additional 1,666,189 shares during the period. Glass Wealth Management Co LLC lifted its position in shares of Pfizer by 0.7% in the 4th quarter. Glass Wealth Management Co LLC now owns 104,395 shares of the biopharmaceutical company's stock worth $2,770,000 after purchasing an additional 709 shares during the period. Finally, Snider Financial Group purchased a new stake in shares of Pfizer in the 4th quarter worth approximately $362,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently weighed in on PFE. Leerink Partners lowered their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research report on Wednesday, April 30th. BMO Capital Markets lowered their price target on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. HSBC lowered their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Wolfe Research boosted their price objective on shares of Pfizer from $22.00 to $23.00 and gave the stock an "underperform" rating in a research note on Wednesday, April 30th. Finally, Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, six have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $28.55.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.13 during midday trading on Thursday, reaching $25.45. The company's stock had a trading volume of 27,104,580 shares, compared to its average volume of 41,625,077. The firm has a market capitalization of $144.66 billion, a PE ratio of 18.44, a P/E/G ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The stock has a fifty day moving average of $23.62 and a 200 day moving average of $24.83. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.82 earnings per share. On average, equities analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.76%. Pfizer's payout ratio is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.